In the early stages of the pandemic, Moderna (MRNA) stock gained significant traction as it became a front-runner in providing a vital product: a coronavirus vaccine. This breakthrough allowed Moderna to leap from a clinical-stage biotech firm to a profitable commercial entity in just a few months, generating billions in revenue. However, the company has recently faced challenges as vaccine sales have declined and its second major product—the respiratory syncytial virus (RSV) vaccine—has not met growth expectations. Despite these setbacks, Moderna has been making strides in cost management and has updated its research focus to include promising new projects. Recently, the stock has appreciated over 30% within a month, signaling investor interest.
Nevertheless, for those considering a sound investment in the biotech sector, Moderna may not be the most reliable option. The company’s potential recovery depends on significant future milestones, like achieving cash breakeven by 2028 and launching new products. This uncertainty makes it less appealing for cautious investors.
Conversely, Vertex Pharmaceuticals (VRTX) emerges as a favorable choice for both cautious and aggressive investors. Vertex has established itself as a leader in cystic fibrosis (CF) treatment, holding the top position globally in this market. The company’s groundbreaking CFTR modulators have proven effective, correcting a defective protein associated with the CFTR gene. Its latest products, Trikafta and Alyftrek, which were approved in 2019 and 2024 respectively, target nearly 95% of CF patients. Vertex is also developing additional therapies to address the remaining percentage of patients who are unresponsive to existing drugs, ensuring its competitive edge well into the next decade.
Vertex’s CF drugs have been instrumental in driving substantial revenue growth; the company reported an 11% rise in total revenue, surpassing $3 billion in the latest quarter, indicating a robust sales trajectory fueled by these successful products. Furthermore, Vertex has been expanding its product lineup, achieving recent approvals for Casgevy, aimed at treating blood disorders, and Journavx, a novel pain management solution. The latter addresses a crucial need in the market for effective, non-opioid pain relief, garnering positive reception from both healthcare providers and patients, with over 300,000 prescriptions filled since its release in March.
Over the last five years, Vertex stock has nearly doubled in value, and it has gained about 15% just in this year, reflecting consistent long-term performance. Current valuation metrics indicate that Vertex trades at 25 times forward earnings estimates, slightly down from previous levels. While not the cheapest option on the market, this price is reasonable considering the company’s established leadership in its specialty and expanding range of products.
It’s worth noting that, like any stock, Vertex is not immune to fluctuations, and its short-term performance may vary. However, the company’s financial stability and diverse product offerings position it for continued success in the biotech landscape, making it a more attractive investment than Moderna at this time.
